Veenstra H, Jacobs P, Dowdle E B
Department of Clinical Science and Immunology, University of Cape Town, South Africa.
Cell Immunol. 1996 Jul 10;171(1):68-73. doi: 10.1006/cimm.1996.0174.
We have previously shown that peripheral blood lymphocytes from patients with chronic lymphocytic leukemia (CLL) express increased amounts of the minor p35 form of class II invariant chain (Ii) relative to the major p33 form. In this report we demonstrate in Western blots that in CLL lymphocytes, but not in normal or Epstein-Barr virus-transformed normal lymphocytes, p35 and p33 Ii form sodium dodecyl sulfate (SDS)-resistant complexes with class II alpha and beta chains and that these complexes form an abnormally large proportion of the total class II molecules. Others have shown that stable SDS-resistant alpha-beta complexes are only formed upon binding of exogenous antigenic peptides for presentation at the cell surface. Large amounts of p35 Ii remaining in the endoplasmic reticulum and capable of forming stable complexes with alpha and beta chains could compete with endogenous antigenic peptides for available class II peptide binding sites. The presentation of endogenous tumor antigens would thus be prevented, leading to the escape of the CLL clone from immunological surveillance.
我们之前已经表明,相对于主要的p33形式,慢性淋巴细胞白血病(CLL)患者的外周血淋巴细胞表达的II类恒定链(Ii)的次要p35形式的量增加。在本报告中,我们通过蛋白质免疫印迹法证明,在CLL淋巴细胞中,而非正常或爱泼斯坦-巴尔病毒转化的正常淋巴细胞中,p35和p33 Ii与II类α链和β链形成耐十二烷基硫酸钠(SDS)的复合物,并且这些复合物在总II类分子中占异常大的比例。其他人已经表明,稳定的耐SDS的α-β复合物仅在外源抗原肽结合以在细胞表面呈递时形成。大量保留在内质网中并能够与α链和β链形成稳定复合物的p35 Ii可能会与内源性抗原肽竞争可用的II类肽结合位点。因此,内源性肿瘤抗原的呈递将被阻止,导致CLL克隆逃避免疫监视。